AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis

Recent development of the chemical inhibitors specific to oncogenic KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog) mutants revives much interest to control KRAS-driven cancers. Here, we report that AIMP2-DX2, a variant of the tumor suppressor AIMP2 (aminoacyl-tRNA synthetase-interacting multi-f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Gyu, Choi, Yongseok, Lee, Yuno, Lim, Semi, Kong, Jiwon, Song, JaeHa, Roh, Younah, Harmalkar, Dipesh S., Lee, Kwanshik, Goo, Ja-il, Cho, Hye Young, Mushtaq, Ameeq Ul, Lee, Jihye, Park, Song Hwa, Kim, Doyeun, Min, Byung Soh, Lee, Kang Young, Jeon, Young Ho, Lee, Sunkyung, Lee, Kyeong, Kim, Sunghoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095880/
https://www.ncbi.nlm.nih.gov/pubmed/35546148
http://dx.doi.org/10.1038/s41467-022-30149-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095880/
https://www.ncbi.nlm.nih.gov/pubmed/35546148
http://dx.doi.org/10.1038/s41467-022-30149-2

Ejemplares similares